Healthcare / BiotechnologyTel Aviv
$321.90
-6.50 (-1.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.0M · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.1%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-11.7M · FCF $-10.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $219000.00 | $118000.00 | $63000.00 |
| Net Income | $-11.7M | $-11.7M | $-7.1M | $-26.0M | $-7.8M |
| EBITDA | $-16.3M | $-16.3M | $-7.7M | $-26.8M | $-8.0M |
| EPS | -1.98 | -1.98 | -1.53 | -5.60 | -1.72 |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Operating Margin | — | — | -4619.6% | -9026.3% | -16384.1% |
| Net Margin | — | — | -3261.2% | -22050.8% | -12455.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.00 | 0.01 |
| Current Ratio | 12.19 | 12.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.9M | $-10.9M | $-11.0M | $-11.0M | $-9.6M |
| Returns | |||||
| ROE | -34.1% | -34.1% | -26.6% | -87.4% | -14.8% |
| Valuation | |||||
| P/B | 55.46 | 55.46 | 105.52 | 81.39 | 66.91 |
| Growth & Yield | |||||
| Revenue Growth | — | — | 85.6% | 87.3% | — |
| EPS Growth | -29.4% | -29.4% | 72.7% | -225.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-51.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.53 → -1.98
Residual
-51.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.